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Background
Safety and tolerability of the VRC/NIAID DNA and rAd5
HIV-1 vaccines administered by intramuscular (IM), sub-
cutaneous (SC), and intradermal (ID) routes of adminis-
tration were evaluated in VRC 011.
Methods
60 subjects (18–50 yrs) were randomized to 6 schedules.
Group 1 (n = 30) received 3 DNA prime vaccinations
(Wks 0,4,8) and Group 2 (n = 30) received a recombinant
adenoviral vector (rAd5) prime vaccination (Wk 0). Both
groups received rAd5 booster at Wk 24. Subjects were
equally randomized to receive prime injections by IM, SC
and ID routes. DNA dosage was 4 mg for IM and SC; 0.4
mg for ID injections. rAd5 dosage was 1010 PU by all
routes. Half of the subjects in each group had pre-existing
Ad5 neutralizing antibody.
Results
27/30 Group 1 subjects completed 3 DNA primes; 30/30
Group 2 subjects completed rAd5 prime by the assigned
route. Local pruritis was reported following 3/30 DNA ID
prime, 6/10 rAd5 ID prime and 2/10 rAd5 SC prime injec-
tions (but not after DNA SC, DNA IM or rAd5 IM injec-
tions). Superficial skin lesions were observed following 5/
10 rAd5 ID injections. Small nodules at the injection site
were reported following 1/30 DNA ID injections, 3/10
rAd5 ID injections and 2/10 rAd5 SC injections.
Conclusion
All routes were well tolerated. Local and systemic reac-
togenicity profiles were acceptable for additional studies.
Local reactions for ID and SC injections had different
characteristics compared to the IM injections, which have
typically been used for these vaccines in prior phase I/II
studies.
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